Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Oct 28, 2011

NEW YORK (GenomeWeb News) – Bernd Brust has resigned as the president of molecular medicine at Life Technologies "in order to pursue other opportunities," the company said in a filing with the US Securities and Exchange Commission this week. Brust has led the molecular medicine business unit since January, when it was created to help the company transition to next-gen sequencing in the clinic. He previously was Life Tech's president of commercial operations. Life Tech said that Brust will continue to serve as a consultant through Dec. 31 "to assist the company with various endeavors."

David Macdonald has been named CEO at Agendia. He replaces Bernhard Sixt, who led the Dutch diagnostics firm since its founding in 2003. Sixt will remain with Agendia in an "advisory capacity," the firm said.

Macdonald has served as Agendia's chief operating officer since last year. He previously worked at Quest Diagnostics, Behring Diagnostics, and Novo Medical. Macdonald holds a BS in management and finance from Northeastern University and an MBA from Babson College. Agendia also said that Coferon CEO Colin Goddard has joined its supervisory board of directors.

Arrowhead Research has appointed Bruce Given as its COO. Given previously served as CEO of Leonardo Biosystems, a nanotechnology company in which Arrowhead holds a minority stake. He was also a director of Arrowhead subsidiary and RNAi drug developer Calando Pharmaceuticals.

Oxford Nanopore Technologies has hired Kristen Stoops as business development director. Stoops has more than 14 years of business development experience in life sciences technology companies, including a seven-year tenure with software firm Spotfire (now part of Tibco), where she directed all aspects of its commercial partner program in life sciences. From 2006 to 2008, Stoops served as director of informatics business development at Helicos BioSciences, and she served as senior director of strategic marketing and new business development at Merck's Rosetta Biosoftware business unit.

Start-up nanopore sequencing company Genia has made public its management team. Stefan Roever is CEO. He is cofounder and former CEO of Brokat Technologies, an encryption banking software company, and serves as chairman of WRS Materials.

Roger Chen, chief technical officer, has a background in analog-mixed signal electronics. He has worked at semiconductor firm Maxim Integrated Products and has launched more than 50 integrated circuits that are currently in production today.

Randy Davis is vice president of research and development. Previously, he worked at National Semiconductor and Maxim Integrated Products. He has also managed the University of California, San Francisco, Comprehensive Cancer Center's microarray and genomic analysis core labs.

Pratima Rao is vice president of marketing. She has held various senior management positions in both semiconductor and life science companies, including at Maxim Integrated Products and Affymetrix.

The Ontario Genomics Institute has appointed three new members to its board of directors including Jack Gauldie, director of the Institute for Molecular Medicine and Health and a professor at McMaster University; Caroline Popper, founder and president of the life sciences consulting firm Popper and Company; and Robert Roberts, president and CEO of the University of Ottawa Heart Institute and director of the Ruddy Canadian Cardiovascular Genetics Centre.

The Lawrence Livermore National Laboratory has named Penrose Albright to be its new director, a position he will begin in December, taking over from George Miller. Albright is a physicist who has worked in the Department of Defense and the Department of Homeland Security, the White House Office of Science and Technology, and the Defense Advanced Research Projects Agency.

GeneNews said this week that it has appointed Karl Wassman to the newly created position of executive VP of US corporate development to manage its SentinelGx services. Wassman most recently was CEO of Source MDx.

Scripps Research Institute Professor of Chemistry Barry Sharpless has joined Integrated Diagnostics as an advisor in connection with a license agreement the company signed with Scripps for technology that Sharpless developed. Sharpless has 40 years of experience in organic chemistry research and he shared the Nobel Prize in Chemistry in 2001.

Halo Genomics has appointed Mats Bergström to be its VP of sales, based out of the company's new offices in Cambridge, Mass. Bergström has held senior management at Pyrosequencing AB (now part of Qiagen), and at Applied Biosystems (now part of Life Technologies). The company said its new offices will be managed by John Lindsay, a former executive at Millipore, Perseptive Biosystems, and Cohesive Technologies, who will be director of sales and marketing for North America.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.